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Abstract Pro-coagulant and pro-inﬂammatory intramyo-
cardial (micro)vasculature plays an important role in acute
myocardial infarction (AMI). Currently, inhibition of ser-
ine protease dipeptidyl peptidase 4 (DPP4) receives a lot of
interest as an anti-hyperglycemic therapy in type 2 diabetes
patients. However, DPP4 also possesses anti-thrombotic
properties and may behave as an immobilized anti-coagu-
lant on endothelial cells. Here, we studied the expression
and activity of endothelial DPP4 in human myocardial
infarction in relation to a prothrombogenic endothelial
phenotype. Using (immuno)histochemistry, DPP4 expres-
sion and activity were found on the endothelium of intra-
myocardial blood vessels in autopsied control hearts
(n = 9). Within the infarction area of AMI patients
(n = 73), this DPP4 expression and activity were signiﬁ-
cantly decreased, coinciding with an increase in Tissue
Factor expression. In primary human umbilical vein
endothelial cells (HUVECs), Western blot analysis and
digital imaging ﬂuorescence microscopy revealed that
DPP4 expression was strongly decreased after metabolic
inhibition, also coinciding with Tissue Factor upregulation.
Interestingly, inhibition of DPP4 activity with diprotin A
also enhanced the amount of Tissue Factor encountered
and induced the adherence of platelets under ﬂow condi-
tions. Ischemia induces loss of coronary microvascular
endothelial DPP4 expression and increased Tissue Factor
expression in AMI as well as in vitro in HUVECs. Our data
suggest that the loss of DPP4 activity affects the anti-
thrombogenic nature of the endothelium.
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Research on coronary perfusion and restoration thereof
after acute myocardial infarction (AMI) has largely been
focused, for obvious reasons, on the larger branches of the
coronary vasculature located on the epicardium. In the last
two decades, however, the role of the smaller intramyo-
cardial microvasculature has gained signiﬁcant interest.
Dysfunction of the intramyocardial microvasculature,
speciﬁcally the endothelium, following AMI is suggested
to relate to left ventricle remodeling, contractility and
cardiac events, such as reinfarction and death [6, 9, 18, 40].
Also, hindered perfusion of the ischemic myocardium after
restoration of coronary ﬂow, known as no-reﬂow or coro-
nary microvascular obstruction (MVO), might point to
dysfunctional coronary microvasculature and associates
with larger infarct size and poor clinical outcome [29, 39].
A multitude of factors may contribute to MVO including
vasospasms, distal embolization, capillary plugging [24,
31]. A role for in situ thrombosis in MVO is debated [31],
but the extrinsic (Tissue Factor-dependent) coagulation
pathway was shown to play a role in MVO in rabbits [21,
22]. We have reported on structural and functional aber-
rations of the coronary microvasculature in AMI patients
such as basement membrane thickening, adhesion molecule
accumulation and products of non-enzymatic glycation
(AGEs), as markers of a pro-inﬂammatory endothelium [3,
8]. It was also shown that a pro-inﬂammatory phenotype of
the coronary microvasculature can induce cardiac ﬁbrosis
[28]. A post-AMI shift towards a more pro-inﬂammatory
and pro-coagulant endothelial phenotype may therefore be
involved in reduced coronary ﬂow. During our studies we
observed unexpectedly—as presented below—a marked
decrease of microvascular endothelial dipeptidyl peptidase
4 (DPP4) expression in recently infarcted human hearts.
DPP4, also known as CD26, is expressed by microvas-
cular endothelial cells in humans (i.e. in liver, spleen, lungs
and brain) and in the hearts of rats [23, 34]. This serine
exopeptidase terminally digests proteins and peptides
containing proline in the penultimate position [10]. Its
substrates include at least nine chemokines, neuropeptide Y
and glucagon-type peptide-1 (GLP-1) [15, 23, 52]. Because
it inactivates GLP-1, inhibition of DPP4 receives a lot of
continuing interest as an anti-hyperglycemic therapy in
type 2 diabetes [15]. In addition, recent publications sug-
gest cardioprotective properties for GLP-1 analogues and
pharmaceutical or genetic inhibition of DPP4 in different
animal models of AMI [27, 47].
On the other hand, another known DPP4 substrate
is ﬁbrin and via cleaving N-terminal Gly-Pro from the
ﬁbrin a-chain, DPP4 can inhibit ﬁbrin polymerization
and clot formation [25, 42]. As such DPP4 may behave
as an immobilized anti-coagulant on (microvascular)
endothelium. Consequently, we asked ourselves whether
the loss of coronary microvascular DPP4 after AMI
relates to the endothelial phenotype shift towards a more
pro-coagulant state and the induction of situ thrombosis
as a possible inducer of MVO after AMI.
In the present study we evaluated a putative relation
between DPP4 expression and pro-coagulant microvascu-
lature in the infarcted human heart and the occurrence of
thrombi in the coronary microvasculature. In addition,
DPP4 activity was studied in relation to platelet adhesion in
human umbilical vein endothelial cells (HUVECs).
Methods
Patients
A total of 82 autopsied patients were included in the study
(Table 1). 73 Patients showed a recently developed left
ventricular AMI [decreased lactate dehydrogenase (LDH)
staining of the affected myocardium]. Nine patients who
died without heart disease were included as controls.
Sampling for (immuno)histochemical analysis was per-
formed as in [3]. From the excised hearts 1 cm cross sec-
tions were made. In these cross sections the infarction area
was determined using lactate dehydrogenase (LDH) stain-
ing. From each AMI patient, a sample of heart tissue was
taken from the center of the LDH-determined infarction
area and a sample was taken from the non-infarcted right
ventricle as an internal control. In control patients a tissue
sample was taken from the anterior wall of the left ven-
tricle. The study protocol was approved by the ethics
committee of the VU Medical Center, and executed
according to the principles of the Declaration of Helsinki.
Microscopic criteria [36] were used to estimate infarct
duration and to categorized into ﬁve phases of infarction:
early phase, PMN (polymorphonuclear neutrophils) phase,
chronic phase infarctions, early phase reinfarctions
(chronic phase as well as early phase morphology) and
PMN-phase reinfarctions (chronic phase as well as PMN-
phase morphology) and corresponded with the clinical
evaluation of AMI.
DPP4 enzymatic activity
A histochemical azo-coupling reaction was performed on
5 lm frozen heart tissue sections to identify DPP4 enzy-
matic activity. The slides were ﬁxed in chloroform and
acetone (1:1 v/v) and were incubated with the substrate
glycyl-proline-4-beta-naphthylamide (Sigma St. Louis,
MO, USA) dissolved in N,N-dimethylformamide (Merck,
Haarlem, The Netherlands) and the azo-dye Fast Blue BB
Salt (G.T. Gurr Ltd, London, UK) dissolved in PBS, ﬁxed
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123again in 4% formalin mounted in Immu-mount (Shandon,
Dreieich, Germany) and analyzed for the percentage of
vessels positive for DPP4 activity.
Primary antibodies
For immunohistochemistry the following antibodies were
used: mAb against DPP4 (1:100) (Serotec, Oxford, UK),
mAb against CD31 (1:40) (Dako, Glostrup, Denmark),
mAb against CD68 (1:400) (Dako), mAb against Tissue
Factor (1:50) (Acris, Herford, Germany), and mAb against
complement factor C3d (1:1,500) [36]. For digital imaging
microscopy the following antibodies were used: mAb
against DPP4 (1:100) (Serotec), mAb against Tissue Factor
(1:50) (Acris) and pAb against nitrotyrosine (1:50) (Invit-
rogen Corporation, Carlsbad, CA, USA). For Western blot
analysis the following antibodies were used: mAb against
DPP4 (1:100) (Serotec) and mAb against Tissue Factor
(1:50) (Acris). For all Abs PBS controls (Fig. 1a, right
panel) and irrelevant Abs (IgG1), tested at similar con-
centrations, were negative.
Immunohistochemistry
Cryostat sections (5 lm) were ﬁxed in chloroform and
acetone (1:1 v/v) and blocked by 3% (v/v) H2O2/PBS.
Serial slides were incubated in normal rabbit serum
(Dakopatts) [1:50 in 1% (w/v) BSA/PBS], incubated with
primary antibodies (in BSA/PBS), incubated with rabbit-
anti-mouse-HRP (Dakopatts) (1:25 in BSA/PBS), incu-
bated in 0.5 mg/ml 3,30-diaminobenzidine tetrahydrochlo-
ride (DAB, Sigma, St. Louis, MO, USA) in 0.01% (v/v)
H2O2/PBS and counterstained with hematoxylin.
Three investigators (P.A.J.K., N.H. and I.K.) indepen-
dently scored all slides. The total number of blood vessels
was determined with CD31. The percentage of DPP4- and
Tissue Factor-positive blood vessels was then determined
and equated for slide areas.
Cell culture
Freshly isolated HUVECs were cultured in M199 culture
medium containing heat-inactivated human serum (10%
v/v), fetal calf serum (10% v/v), 2,500 Units heparin and
100 lg/ml endothelial cell growth factor (cells cultured in
this medium served as controls). For metabolic inhibition,
cells were incubated in 0.9 mM CaCl2 H2O, 20 mM
2-deoxy-D-glucose (Sigma, St. Louis, MO, USA), 106 mM
NaCl, 5 mM NaCN, 3.8 mM NaHCO3, 4.4 mM KCl and
1 mM MgCl2 H2Oi nH 2O (pH 6.6). Apocynin (100 lM),
diprotin A (10 mM), polymyxin B sulfate (2 lg/ml) and
TNFa (10 lg/ml) (all Sigma) were incubated for 6 h.
Western blotting
After culturing in culture medium or metabolic inhibition
buffer, HUVECs were lysed in buffer containing 0.01%
NP-40, 2.5 mM Tris–HCl, (pH 8.0), 150 lM NaCl, and
5 mM EDTA in H2O. Protein concentration was deter-
mined using the BCA protein assay kit (Pierce, Rockford,
IL, USA). Then reducing (b-mercaptoethanol-containing)
sample loading buffer [0.25 M Tris (pH 6.8), sodium
dodecyl sulfate (SDS), glycerol, 2-mercaptoethanol, bro-
mophenol blue] was added and the samples were mixed
and heated at 95C for 5 min. Proteins were separated via
electrophoresis and blotted onto nitrocellulose membranes,
incubated with primary antibodies, incubated with rabbit-
anti-mouse-HRP (1:1,000) and then visualized by
Enhanced ChemiLuminescence (ECL; Amersham, Buck-
inghamshire, UK).
Digital imaging microscopy
HUVECs were grown in 4-well chamber slides (Nalge
Nunc International, Naperville, IL, USA). After treatment,
the cells were ﬁxed in 4% formaldehyde, permeabilized
with acetone–methanol (70–30%), incubated with primary
Table 1 Patient characteristics
n Infarct duration Male/female* Age range (mean ± SE)

Control 9 NA 2/7 58–86 (68 ± 5)
Early-phase infarction 15 0–12 h 14/1 23–88 (65 ± 4)
PMN-phase infarction 20 12 h–5 days 15/5 47–85 (73 ± 2)
Chronic-phase infarction 10 5–14 days 8/2 42–93 (68 ± 4)
Early-phase reinfarction 16 5–14 days ? 0–12 h 12/4 45–85 (66 ± 3)
PMN-phase reinfarction 12 5–14 days ? 12 h–5 days 10/2 30–85 (65 ± 5)
n = number of patients, NA = not applicable, PMN polymorphonuclear neutrophil
* The male/female composition did not differ signiﬁcantly between the groups (Chi-square test with ordinal gamma test);
 there was no
statistical difference in age between the groups (one-way Anova)
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123antibodies, incubated with donkey-anti-mouse-Alexa 488
(1:40) (DPP4, Tissue Factor) and/or donkey-anti-rabbit-
Alexa 647 (1:40) (nitrotyrosine) and incubated with wheat
germ agglutinin (WGA), (1:40) (Invitrogen) to visualize
cellular membranes (all in 1:2,000 v/v PBS/Tween20).
Slides were covered in mounting medium containing DAPI
(Vector Laboratories Inc, Burlingame, CA, USA) to visu-
alize nuclei and analyzed with a 3I Marianas
TM digital
imaging microscopy workstation (Carl Zeiss, Sliedrecht,
Netherlands). To determine cell viability, cells were
stained with trypan blue and then quantiﬁed. In the digital
imaging microscopy experiments on average 70 cells were
analyzed per condition per donor.
Platelet isolation
Whole blood, obtained from healthy individuals, was
centrifuged at 1509g. The supernatant was 1:1 diluted in
Ca
2?-free Krebs–Ringer buffer (4 mM KCL, 107 mM
NaCl, 20 mM NaHCO3, 2 mM Na2SO4, 19 mM tri-sodium
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Fig. 1 DPP4 in the human
myocardium. a DPP4 positivity
(left panel; arrows) on the
endothelium of intramyocardial
blood vessels (asterisks) and a
PBS control (right panel) in the
heart of a control patient.
Original magniﬁcation 9125.
b DPP4 (left panel; arrows) and
CD31 (right panel; arrows)i n
capillaries in the heart of a
control patient. Original
magniﬁcation 940.
c Percentage of blood vessels
positive for DPP4 protein
(grey bars), and DPP4 activity
(black bars) in control patients
and in infarctions of all
durations. n number of patients.
*p\0.001,
p\0.01,
p\0.05,
#p\0.05, all
compared to control.
d Percentage of blood vessels
positive for DPP4 protein
(black bars) control patients and
non-infarcted myocardium
(right ventricle) of AMI patients
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123citrate, 0.5% (w/v) glucose in H2O) (pH 5.0) and centri-
fuged at 5009g. The obtained non-stimulated platelets
were labeled with calcein (Invitrogen) diluted 2:1 (w/v) in
DMSO and used in a ﬁnal concentration of 300,000/lli n
Ca
2?-free Krebs–Ringer ﬂow buffer (pH 6.1).
Perfusion of HUVECs with platelets
HUVECs were cultured in ﬁbronectin-coated l-Slides VI
0.4
(Ibidi GmbH, Martinsried, Germany) until uniform conﬂu-
ent monolayers were obtained. Prior to perfusion cells were
incubated with either culture medium (controls) or with
culture medium supplemented with Diprotin A (10 mM) or
with TNFa (10 lg/ml) for 6 h. The slides were connected to
two ANTEC syringe pumps [ANTEC (leyden), Zouterwo-
ude, The Netherlands] via a ﬂow kit (Ibidi) to generate a
constant ﬂow rate with a shear stress of 0.35 dyne/cm
2. The
slides were mounted on a Zeiss Axiovert 200m microscope
(Zeiss, Go ¨ttingen, Germany). The HUVECs were perfused
with calcein-labeled platelets for 3 min.
Statistical analysis
Paired or non-paired t tests, Mann–Whitney analysis, Chi-
square test ? ordinal Gamma test, Kruskal–Wallis test ?
Dunns multiple comparison tests or one-way ANOVA ?
Bonferroni’s multiple comparison tests were used when
appropriate.Inﬁgures,valuesare givenasmeans ± standard
error. A p value (two-sided) of less than 0.05 was consid-
ered to represent a signiﬁcant difference.
Results
DPP4 in the human myocardium
In human hearts, DPP4 was found on the endothelium in
larger intramyocardial arteries (Fig. 1a) as well as in ven-
ules and capillaries (Fig. 1b). Cardiomyocytes were nega-
tive for DPP4 in all patients. DPP4 was found in the hearts
of control patients as well as in the infarcted myocardium
of AMI patients (Fig. 1c, grey bars). However, the per-
centage of DPP4-positive blood vessels was signiﬁcantly
lower in infarctions of all durations compared with con-
trols, except for early-phase infarctions (PMN phase
p\0.001, chronic phase p\0.01, early- and PMN-phase
reinfarctions p\0.05). In early-phase infarctions, the
percentage of DPP4-positive blood vessels was markedly
lower than in controls, but not signiﬁcantly. DPP4
expression coincided with enzymatic activity in all infarct
durations as well as in controls (Fig. 1c, black bars).
Pearson correlation analysis revealed that in the controls
and all phases of infarction patients’ age did not correlate
with the DPP4 expression score: control (r
2 = 0.05167),
early phase (r
2 = 0.01368), PMN phase (r
2 = 0.1468),
chronic phase (r
2 = 0.001577), early-phase reinfarction
(r
2 = 0.05768) and chronic-phase reinfarction (r
2 =
0,02594) (p[0.05 in all groups). Notably, in chronic-
phase infarctions DPP4 positivity was also observed in
blood vessels, lymphocytes and granulation tissue (not
shown).
In non-infarcted myocardium from AMI patients, no
reduction in the percentage of DPP4-positive blood vessels
was found compared to controls (Fig. 1d).
Tissue Factor in the human myocardium
As DPP4 may act as an anti-coagulant enzyme, the
expression of pro-coagulant Tissue Factor was analyzed in
control hearts and in PMN-phase infarctions and PMN-
phase reinfarctions.
In control hearts, low levels of Tissue Factor were found
in the sub-endothelial layer of a small number of intramy-
ocardial blood vessels (Fig. 2a). Cardiomyocytes were
negative for Tissue Factor. In the infarcted myocardium, the
percentage of Tissue Factor-positive intramyocardial blood
vessels signiﬁcantly increased (PMN-phase infarctions
p\0.01, PMN-phase reinfarctions p\0.001; Fig. 2a, b).
Tissue Factor was found in the endothelial- and sub-
endothelial layer of blood vessels (Fig. 2c, d) as well as on
damaged cardiomyocytes that also stained positive for
complement (factor C3d, not shown). As macrophages can
also express Tissue Factor [13], we examined putative
co-localization between macrophage marker CD68 and
Tissue Factor. On Tissue Factor-positive endothelial cells
no CD68-positive macrophages were found (not shown).
As Tissue Factor is a coagulation initiator we analyzed
the presence of thrombi in the intramyocardial (micro)vas-
culature. We detected CD31-positive thrombi in the lumen
of intramyocardial blood vessels in only 5 out of 32 ana-
lyzed patients (not shown). In these ﬁve patients, the per-
centage of intramyocardial blood vessels positive for Tissue
Factor was higher than in AMI patients without detectable
thrombi, although not signiﬁcant (p = 0.06).
DPP4 and Tissue Factor expression in endothelial cells
DPP4 expression was decreased in those parts of the heart
that were exposed to ischemia. To investigate whether
ischemia by itself can induce the loss of endothelial DPP4,
its expression was studied in metabolically inhibited
HUVECs via digital imaging microscopy (Fig. 3a–c).
In control cells (Fig. 3aI), DPP4 was abundantly present
on the cell surface as well as in the cytoplasm. DPP4
expression was reduced signiﬁcantly after 3 (p\0.001)
and 6 h (p\0.001) of metabolic inhibition (Fig. 3aII–III,
Basic Res Cardiol (2012) 107:233 Page 5 of 13
123b). These results were veriﬁed by Western blot analysis
(Fig. 3c). Notably, after 3 and 6 h of metabolic inhibition
cell viability was still more that 95%, as determined by
trypan blue staining (not shown).
In contrast, Tissue Factor was induced reaching statis-
tical signiﬁcance after 6 h of metabolic inhibition
(p\0.001; Fig. 3dI–III, e).
As exogenous reactive oxygen species (ROS), which are
produced also during ischemia, can be involved in endo-
thelial Tissue Factor expression [30], involvement of ROS
in ischemia-induced Tissue Factor and/or reduced DPP4
expressions in HUVECs was analyzed via digital imaging
ﬂuorescence microscopy. Nuclear ROS signiﬁcantly
increased after 6 h of metabolic inhibition (p\0.001;
Fig. 4a). The antioxidant and inhibitor of NADPH oxidase-
derived ROS apocynin signiﬁcantly counteracted this
increase (p\0.001; Fig. 4a) as well as the effects of
metabolic inhibition on the expressions of both DPP4 and
Tissue Factor (p\0.001; Fig. 4b, c). These results suggest
that the effects induced by metabolic inhibition on DPP4
and Tissue Factor expression involve NADPH oxidase-
derived ROS.
In addition, the putative effects of DPP4 activity inhi-
bition by diprotin A on nuclear ROS and on Tissue Factor
expression were analyzed in HUVECs via digital imaging
microscopy. In contrast to metabolic inhibition Diprotin A
induced a signiﬁcant decrease in nuclear ROS (p\0.001;
Fig. 4d). Remarkably, diprotin A did induce a signiﬁcant
increaseinendothelialTissueFactorexpression(p\0.0001;
Fig. 4e), which was veriﬁed via western blot analysis
(Fig. 4f). To conﬁrm that the effects of diprotin A on nuclear
ROS and Tissue Factor expression were not due to endotoxin
contamination, the effects of diprotin A on nuclear ROS and
Tissue Factor expression were analyzed in the presence of
the endotoxin antagonist polymyxin B. Polymyxin B did
not affect the diprotin A-mediated effects (3 independent
experiments; not shown).
Inhibition of DPP4 activity induces adherence
of platelets to endothelial cells
Aggregation of platelets to endothelial cells is a sign of
thrombogenicity. Here we tested whether inhibition of
DPP4 activity by diprotin A in HUVECs leads to increased
adherence of non-stimulated platelets under ﬂow condi-
tions. Platelet adhesion-inducing TNFa was used as a
positive control [2].
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Fig. 2 Tissue Factor expression in the human myocardium. a Per-
centage of Tissue Factor-positive blood vessels in control patients,
PMN-phase infarctions and PMN-phase reinfarctions. n = number of
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123In untreated HUVECs, very few platelets adhered,
mainly as solitary cells (upward arrows; Fig. 5a).
Unbound platelets were recognized as unfocussed blurred
stripes as they passed (dotted arrows). TNFa induced a
marked increase in adhering platelets (Fig. 5b). These
platelets adhered both individually (upward arrows) and
as strings of platelets (downward arrows) of various
length, sometimes up to 20 or more platelets per string.
These strings were formed within seconds. Aggregation of
platelets was not observed. Similarly, diprotin A induced
a marked increase in adhering platelets compared to
untreated cells (Fig. 5c). Again, platelets adhered both
individually (upward arrows) and as strings of platelets
(downward arrows), but did not aggregate. Interestingly,
the adherence of platelets was in majority temporary in
these conditions. Adhered platelets sometimes released
after seconds, but most platelets adhered for longer and
released after minutes. These results thus indicate that
loss of DPP4 activity in endothelial cells can induce a
prothrombotic status.
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Fig. 3 DPP4 and Tissue Factor
expression in ischemic
HUVECs 3D-digital imaging
microscopy images of aI–III
DPP4 (green), membranes
(WGA red) and nuclei (DAPI
blue) and of dI–III Tissue
Factor (green), membranes
(WGA red) and nuclei (DAPI
blue) in control cells and after 3
or 6 h of metabolic inhibition.
Original magniﬁcation 940
(n = 5). b Quantiﬁcation of
DPP4 microscopy analysis
(relative difference compared to
control cells). *p\0.001,
p\0.001. c Western blot
analysis of DPP4 expression in
control cells or after 3 or 6 h of
metabolic inhibition. The same
amounts of protein were loaded
(n = 3). e Quantiﬁcation of the
Tissue Factor expression
microscopy analysis (relative
difference compared to control
cells) *p\0.001
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123Discussion
Currently, DPP4 receives an attention as a target for anti-
hyperglycemic therapy in type 2 diabetes patients and
cardioprotective properties have been ascribed to GLP-1
analogues and to DPP4 inhibition in AMI. However, DPP4
can act as a proteolytic enzyme, a receptor and a
costimulatory protein and has been shown to be involved in
a wide range of different cellular functions [10]. We now
show that enzymatically active DPP4 is expressed by the
endothelium of the intramyocardial (micro)vasculature in
humans. Interestingly, this DPP4 expression and activity
decreased within the infarction area of AMI patients,
coinciding with increased microvascular Tissue Factor
expression. In HUVECs, metabolic inhibition induced
ROS-dependent loss of DPP4 and concomitant Tissue
Factor upregulation. And inhibition of DPP4 activity
induced adhesion of platelets. Taken together, our data
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Fig. 4 Nuclear nitrotyrosine,
Tissue Factor and DPP4
expression in ischemic
HUVECs Using 3D-digital
imaging microscopy, nuclear
nitrotyrosine (a), cellular DPP4
(b), and Tissue Factor
(c) expression quantiﬁed in
control cells or after 3 or 6 h of
metabolic inhibition (MI) with
or without apocynin (100 lM)
(relative difference compared to
control cells) (n = 4).
a *p\0.001,
p\0.001;
b *p\0.001,
p\0.001;
c *p\0.001,
p\0.01.
3D-digital imaging microscopy
of nuclear nitrotyrosine (d) and
cellular Tissue Factor
(e) expression were quantiﬁed
in HUVECS cultured under
control conditions with or
without diprotin A (10 mM) for
6 h (relative difference
compared to control cells)
(n = 3). d *p\0.001,
e *p\0.0001. Tissue Factor
expression was veriﬁed via
western blot analysis (f)
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123suggest a direct relation between DPP4 activity and
thrombogenic status of endothelial cells.
The post-infarct decrease of intramyocardial microvas-
cular DPP4 expression may be a direct result of the
ischemia endured or due to enhanced availability of
inﬂammatory cytokines such as TNFa. Involvement of
ischemia is supported by our ﬁnding that persisting meta-
bolic inhibition markedly reduced DPP4 expression in still
viable human endothelial cells. This seems at variance with
observations in a rat model of hindlimb skeletal muscle
ischemia, in which control muscles did not contain DPP4
mRNA at all, and DPP4 mRNA was induced by ischemia
[37]. However, neither protein levels nor cellular origin of
DPP4 were determined. Furthermore, we observed an
increase of DPP4 in blood vessels within granulation tissue
in chronic-phase infarctions. Therefore, these differences
C diprotin A
B TNFα α
A control
Fig. 5 Diprotin A and TNFa induced platelet adhesion to HUVECs
under perfusion. Example of calcein-labeled platelets adhering to
(unstained) HUVECs; under control conditions (a), pre-treated with
TNFa (b) or diprotin A (c) for 6 h (n = 5). Platelets adhered both as
strings (downward solid arrows) as well as individually (upward solid
arrows). Non-adhered platelets are recognized as blurred stripes as
they pass (dotted arrows)
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123may be related to differences in expression or timing
between muscle cells and endothelial cells. Inﬂammatory
cytokines such as TNFa and IL6 were shown to be
involved in impaired coronary microvascular perfusion
[32, 33, 38, 45, 51]. As TNFa can both reduce DPP4 [48]
and induce Tissue Factor [11, 20], we cannot exclude that
such inﬂammatory cytokine also may contribute to the
effects observed in infarcted hearts [33]. However, it does
not contribute to the observations in metabolically inhib-
ited cultured endothelial cells.
Contrary to DPP4, Tissue Factor was upregulated in the
infarcted heart, both in the intramyocardial microvascula-
ture as well as in damaged cardiomyocytes. This increase
may also result from the ischemia endured, as demon-
strated in endothelial cells in vitro. Tissue Factor expres-
sion was shown earlier in human and animal hearts and was
implicated in mediating reperfusion injury, as Tissue Fac-
tor inhibition resulted in decreased inﬂammation and
infarct size in rabbit and mouse AMI models [12, 14, 22].
Tissue Factor, a member of the cytokine receptor super-
family, initiates blood coagulation through the binding of
FVII/FVIIa [41]. Additionally, the Tissue Factor/FVIIa
complex or Tissue Factor alone can activate different (pro-
inﬂammatory) cellular signaling pathways [17, 41]. Tissue
Factor inhibition was shown by two independent groups to
reduce myocardial infarct size in rabbits, although one
group suggested that this was due not through inhibition of
thrombotic events but through inhibition of inﬂammation
[12], while the other concluded that it reduced intramyo-
cardial coagulation and reduced the no-reﬂow phenomenon
[22].
Platelet adhesion resulting in microvascular plugging
was shown to cause reduced perfusion and no-reﬂow after
AMI [7, 46]. In our in vitro experiments, inhibition of
DPP4 activity induced adherence of non-stimulated plate-
lets to HUVECs under ﬂow conditions. Adherence of non-
stimulated platelets to cytokine- or microparticle-stimu-
lated endothelial cells was shown before [1, 2, 16, 26, 49,
53]. It was shown that platelet adhesion can depend on
Tissue Factor [49, 53], interactions between platelet F11
receptor and endothelial JAM [2] and on secreted von
Willebrand factor (vWf) [1, 16, 26]. It was shown recently
that platelet-derived growth factor CC (PDGF-CC),
released from activated platelets induced Tissue Factor
expression in human microvascular endothelial cells [19].
Although in our platelet adhesion experiments we used
non-stimulated platelets we cannot exclude such a role for
PDGF-CC. In our experiments, platelets adhered individ-
ually and in strings. These strings of platelets indicate a
role for vWf, as it was shown earlier that platelets bind
endothelial cells through vWf in such fashion [1, 16, 26].
Therefore, the reduced presence/activity of DPP4 and
increased presence of Tissue Factor in the post-MI
intramyocardial microvasculature suggests a shift towards
a prothrombogenic status of the endothelium and an
increased risk of intramyocardial thrombosis. However, in
only 5 out of 32 analyzed AMI patients intramyocardial
thrombi were found. As thrombolytic treatment is standard
procedure for AMI patients, prospective thrombi may dis-
solve prior to analysis.
The ischemia-induced effects on DPP4 and Tissue
Factor expressions were inhibited by the antioxidant and
inhibitor of NADPH oxidase-derived ROS apocynin, sug-
gesting ROS involvement in both events. Involvement of
ROS in Tissue Factor expression was reported before. In
primary endothelial cells exogenous superoxide induced
concomitant NADPH oxidase activation and Tissue Factor
expression [30] and LPS induced NOX1-mediated Tissue
Factor expression [43], whereas PAR1/2-induced endo-
thelial Tissue Factor expression was mediated solely via
mitochondrial ROS [5]. Mitochondrial ROS are a potential
candidate for involvement in ischemia-induced Tissue
Factor expression and possibly ischemia-induced loss of
DPP4.
In contrast to ischemia, DPP4 activity inhibition with
diprotin A reduced nuclear ROS production. It was recently
shown that GLP-1 protected endothelial cells against oxi-
dative stress in vitro [44]. However, in the said study the
effects of added GLP-1 on cultured endothelial cells were
investigated and since there is no evidence available so far
that endothelial cells can produce GLP-1 themselves, it is
unlikely that GLP-1 was a factor in our in vitro experi-
ments. Thus, diprotin A most likely reduced ROS inde-
pendent of GLP-1. Remarkably, diprotin A simultaneously
induced a signiﬁcant increase in endothelial Tissue Factor
expression. The fact that diprotin A, even though it lowered
nuclear ROS, did induce Tissue Factor, strongly suggests
that different cellular pathways are involved in Tissue
Factor upregulation induced by ischemia on the one hand
(which increased nuclear ROS) and by diprotin A on the
other (which lowered nuclear ROS). Whether, and if so to
what extent, these different pathways are relevant in the
infarcted heart in vivo remains to be established.
Dysfunction of the intramyocardial microvasculature
following AMI relates to left ventricular remodeling and
cardiac events [6, 9, 18], may relate to no-reﬂow of the
ischemic myocardium and is associated with larger infarct
size and poor clinical outcome [29]. The AMI-induced loss
of DPP4 and concomitant Tissue Factor upregulation we
show here may contribute to this dysfunction. DPP4
activity was also implicated in revascularization of ische-
mic tissues via conversion of neuropeptide Y [37, 52]. Our
observed DPP4 increase in chronic-phase infarctions in
blood vessels within granulation tissue might support such
a role. Alternatively, recent studies show evidence for a
cardioprotective role for pharmacologic inhibition and of
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123genetic depletion of DDP4 in rat- and mouse-myocardial
infarction models [27, 35, 47, 50]. These cardioprotective/
infarct size limiting effects of DPP4 inhibition were largely
attributed to the prevention of GLP-1 degradation. The
cardioprotective effects of increased GLP-1 levels may
involve improved glucose uptake, increased myocardial
cyclic AMP levels and activation of cardioprotective
kinases, such as PKA and AKT [27, 35, 47, 50]. However,
Ban et al. [4] showed novel cardiac and vascular protective
effects of truncated GLP-1(9–36), suggesting that DPP4
also may have cardioprotective effects through the degra-
dation of GLP-1, but possibly also via the before men-
tioned angiogenesis-inducing conversion of neuropeptide
Y[ 37, 52]. Therefore, these studies, and the current study,
highlight that the roles of DPP4 in the heart may be
complex and may have opposing effects. Hence, monitor-
ing of the effects of DPP4 inhibition in patients at risk for-
or with AMI appears warranted.
In conclusion, we show that DPP4 activity is related to
the thrombogenic status of endothelial cells in that lack of
DPP4 activity induces expression of Tissue Factor and
platelet adhesion, and that this relation may have impli-
cations regarding post-AMI dysfunction of the coronary
microvasculature.
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